Skip to main content

Table 1 Cumulative clinical manifestations, autoantibody panels, initial creatine phosphokinase serum levels, and comorbidities of the patients with antisynthetase syndrome

From: High YKL-40 serum levels and its expression in the muscle tissues of patients with antisynthetase syndrome

Antisynthetase syndrome n = 64
Cumulative clinical manifestations
 Muscle involvement 61 (95.3)
 Joint involvement 59 (92.2)
 Lung involvement 57 (89.1)
  Ground-glass 46 (71.9)
  Incipient pneumopathy 40 (62.5)
  Pulmonary fibrosis 14 (21.9)
  Pulmonary nodules 11 (17.2)
 “Mechanic’s hands” 57 (89.1)
 Raynaud’s phenomenon 50 (78.1)
 Fever 46 (71.9)
Autoantibody panels
 Antinuclear factor 52 (81.3)
 Anti-Ro-52 28 (43.8)
 Anti-tRNA aminoacyl transferase 64 (100.0)
  Anti-Jo-1 52 (81.3)
  Anti-PL-12, anti-PL-7 or anti-EJ 12 (18.7)
  Anti-OJ 0
Initial creatine phosphokinase (U/L) 3015 (632–8463)
Comorbidities
 Systemic arterial hypertension 22 (34.4)
 Diabetes mellitus 12 (18.8)
 Hypothyroidism 3 (4.7)
 Acute myocardial infarction 3 (4.7)
 Stroke 1 (1.6)
  1. Data are expressed as mean ± standard deviation (SD); median (interquartile 25th - 75th) or frequency (%)